Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Revenue in DKK (TTM)342.79m
- Net income in DKK-703.74m
- Incorporated1997
- Employees253.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioArctic AB | 393.15m | 146.31m | 9.11bn | 88.00 | 75.10 | 16.35 | 57.61 | 23.16 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | 6,999,943.00 | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Bonesupport Holding AB | 377.24m | 156.38m | 9.97bn | 105.00 | 63.85 | 28.85 | 61.21 | 26.42 | 3.72 | 3.72 | 9.04 | 8.24 | 1.11 | 0.7186 | 6.60 | 5,629,305.00 | 46.20 | -9.08 | 58.31 | -11.28 | 91.51 | 90.25 | 41.45 | -11.65 | 2.46 | -- | 0.0311 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 7.06bn | 1.48bn | 11.26bn | 1.38k | 7.41 | 1.09 | 5.55 | 1.59 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 2.23bn | -2.45bn | 13.62bn | 1.13k | -- | 1.61 | -- | 6.10 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 1.10bn | 275.36m | 17.53bn | 213.00 | 63.59 | 17.76 | 61.66 | 16.00 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 4.82bn | 486.00m | 25.20bn | 2.82k | 59.46 | 6.19 | 32.43 | 5.22 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 9.10bn | 1.62bn | 37.26bn | 3.70k | 22.87 | 7.03 | 18.92 | 4.09 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Zealand Pharma A/S | 342.79m | -703.74m | 37.53bn | 253.00 | -- | 21.95 | -- | 109.47 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Swedish Orphan Biovitrum AB (publ) | 14.77bn | 1.37bn | 63.51bn | 1.75k | 45.37 | 2.66 | 17.91 | 4.30 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Genmab A/S | 16.47bn | 4.35bn | 126.66bn | 2.20k | 29.00 | 3.96 | -- | 7.69 | 66.05 | 66.05 | 249.95 | 483.85 | 0.5037 | -- | 3.09 | 7,474,592.00 | 13.31 | 17.43 | 14.25 | 18.59 | 55.82 | -- | 26.42 | 35.87 | 13.32 | -- | 0.0238 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of Apr 26 2024. Currency figures normalised to Zealand Pharma A/S's reporting currency: Danish Krone DKK
32.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 19 Oct 2023 | 5.65m | 9.02% |
| J.O. Hambro Capital Management Ltd.as of 11 Jan 2024 | 3.13m | 5.00% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.14m | 3.41% |
| Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 2.08m | 3.32% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 1.61m | 2.56% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.52m | 2.42% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.48m | 2.37% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 1.14m | 1.83% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 982.92k | 1.57% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 743.20k | 1.19% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
